Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Clever Culture Systems Taps PSC Biotech to Expand APAS Independence Pharma Sales
Clever Culture Systems appoints PSC Biotech as sole sales agent for APAS Independence, targeting pharmaceutical makers in the US, Canada and Singapore.
Latest Stories — SECTOR DESK
PainChek Expands Sabra Health US Rollout To 23 Care Communities
PainChek expands Sabra US rollout to 23 care communities, securing 808 contracted memory care licences as it targets year-end activation.
Proteomics International Completes Independent Validation of PromarkerEndo to Diagnose Early-Stage Endometriosis
Proteomics International independently validates PromarkerEndo, showing 90% sensitivity for stage IV endometriosis, with commercial availability targeted for FY27.
EBR Systems Resets US Sales Strategy after WiSE Implant Slowdown
EBR Systems resets its US sales strategy after WiSE implants fell to 40 in the September quarter, as Medicare reimbursement rates rise by up to 93%.
Racura Oncology Advances to New RC220 Dose Level in Harness-1 Lung Cancer Trial
Racura Oncology can escalate RC220 to 100mg/sqm in its lung cancer trial after no safety concerns emerged at the initial dose.
Clarity Pharmaceuticals Hits SECuRE Cohort Expansion Main Group Recruitment Target
Clarity Pharmaceuticals hits SECuRE main-group recruitment target, advancing its prostate cancer therapy trial as Phase III planning gets underway.
Cyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China
Cyclopharm’s Technegas unanimously recommended as China’s preferred ventilation agent for lung imaging by seven leading medical bodies.
Optiscan Imaging Moves Closer to Regulatory Clearance of Real-Time Surgical Imaging Platform
Optiscan Imaging submits InVue for FDA 510(k) review, moving its real-time surgical imaging platform closer to US clearance and commercialisation.
Dimerix Achieves First Patient Completion Milestone for DMX-200 Clinical Program
Dimerix’s DMX-200 program reaches a milestone as its first patient completes two years in the extension study, with 93% of eligible patients continuing.
Artrya Wins Five-Year US Commercial Deal with Huntsville Hospital Health System
Artrya lands five-year US deal with Huntsville Hospital Health System; minimum US$0.5m for Salix Coronary Anatomy SaaS, expanding its US footprint.
Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment
Syntara expands Phase 1b trial for SNT-9465, adding 10 participants, new blinded design and Sydney site; top-line data due Q1 2027 to back an IND.
LTR Pharma Final Phase II Report Confirms Fast Absorption for Spontan Intranasal Spray in Treating ED
LTR Pharma's Spontan intranasal ED spray peaks in 10 minutes, six-fold faster than oral vardenafil; Phase II data complete, paving US licensing talks.